[20191031]IF11318_医疗保险D部分中的药品价格谈判.pdf

上传人:任我行 文档编号:28647 上传时间:2022-06-24 发布时间:2019-10-31 格式:PDF 页数:3 大小:433.19KB
下载 相关 举报
[20191031]IF11318_医疗保险D部分中的药品价格谈判.pdf_第1页
第1页 / 共3页
[20191031]IF11318_医疗保险D部分中的药品价格谈判.pdf_第2页
第2页 / 共3页
[20191031]IF11318_医疗保险D部分中的药品价格谈判.pdf_第3页
第3页 / 共3页
亲,该文档总共3页,全部预览完了,如果喜欢就下载吧!
资源描述

1、 https:/crsreports.congress.gov Updated October 31, 2019Negotiation of Drug Prices in Medicare Part DThe 116th Congress is considering a number of approaches to address prescription drug prices and spending, including proposals to allow the Secretary of Health and Human Services (the Secretary) to n

2、egotiate prices in the Medicare Part D program. This In Focus provides an overview of how drug prices are established under Part D and describes elements of various proposals for Secretarial negotiation. Overview of Medicare Part D Congress created a voluntary Medicare outpatient prescription drug b

3、enefit, Part D, in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA; P.L. 108-173). The program started in 2006, and about 46 million Medicare beneficiaries are currently enrolled. In 2019, Part D spending is estimated to reach approximately $98 billion. Part D is also

4、 the primary source of drug coverage for individuals enrolled in both Medicare and the state-federal Medicaid program (dual eligibles). (See CRS Report R40425, Medicare Primer, and CRS Report R40611, Medicare Part D Prescription Drug Benefit.) Part D coverage is provided by private health payers (pl

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告